ClinicalTrials.gg
Active, not recruitingNCT06572228AIM4:Next StepUpdated May 22, 2026

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

A Phase 4 interventional study of dupilumab and Matching Placebo in Asthma, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 77 sites in 6 countries. Open to participants aged 12 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
12 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Enrollment
16th of 31
120 · median 120
Started
2024
with 4 others
Phase 4
14 of 31
5 open now
Primary completion
2027-04
later than 6 of 11 live
Registered
29th of 31
by date
Lead sponsor
3 of 31
Regeneron Pharmaceuticals

Among the 31 studies testing dupilumab in Asthma, this one is the 16th largest by enrollment, is one of 5 that started in 2024, is one of 14 in phase 4, reaches primary completion later than 6 of the 11 other live ones, and was the 29th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication.

The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA.

The study is also looking at:

  • What side effects may happen from taking dupilumab
Read the detailed description

This study is a Phase 3b in Canada Minors will not be enrolled in Denmark

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Uncontrolled
  • Severe exacerbations
  • Type 2 Inflammation
  • Elevated blood eosinophils
  • Increased Fractional exhaled Nitric Oxide (FeNO)
  • Atopy and elevated Immunoglobulin E (IgE)
04

Who can participate

Ages eligible
12 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Diagnosis of asthma for ≥12 months, based on the Global Initiative for Asthma (GINA) 2023 guidance document
  2. Existing treatment with medium dose ICS/LABA (>250 to 500 μg/day of fluticasone propionate DPI or equivalent, per GINA 2023 guidance document) for at least 3 months with a stable dose ≥1 month prior to visit 1
  3. Participants requiring a maximum of 3 controllers for their asthma will be considered eligible for this study
  4. Pre-bronchodilator , as defined in the protocol
  5. Reversibility of at least 12% and 200 mL in FEV1 after the administration of 200 to 400 μg albuterol/salbutamol at screening OR a documented history of ≥20% reduction in the FEV1, as defined in the protocol
  6. Demonstrated adherence to medium dose ICS/LABA on at least 80% of days during the run-in period
  7. ACQ-5 score ≥1.5 at screening (visit 1)
  8. History of ≥1 severe exacerbation(s) in the previous year before visit 1, but not in the 30 days immediately preceding visit 1
  9. Biomarker criteria: Baseline blood eosinophil count ≥300 cells/μL at visit 1 (\~90% of population), as defined in the protocol

Key Exclusion Criteria:

  1. Diagnosis of (COPD) or other lung diseases which may impair lung function and interfere with treatment assessments
  2. Clinical evidence of lung disease(s) other than asthma or imaging (Chest X-ray, computed tomography (CT), magnetic resonance imaging [MRI]) with significant findings within 12 months of visit 1 and up to and including the baseline visit (visit 3)
  3. A participant who experiences a severe asthma exacerbation at any time from 1 month prior to the screening visit (visit 1) up to and including the baseline visit (visit 3), as defined in the protocol
  4. Weight is less than 30 kilograms
  5. Current smoker or cessation of smoking within 6 months prior to visit 1 or previous smoker with a smoking history ≥10 pack-years
  6. Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study, as defined in the protocol
  7. Participants cannot be on systemic at any time from 1 month prior to the screening visit (visit 1) through the duration of the run-in period

NOTE: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Dupilumab + ICS/LABA

    Randomized 1:1

    Drug: dupilumab · Drug: ICS/LABA

  • Placebo comparator
    Placebo + ICS/LABA

    Randomized 1:1

    Drug: Matching Placebo · Drug: ICS/LABA

Interventions

  • Administered by subcutaneous (SC) injection

    Also known as: Dupixent®, REGN668, SAR231893

  • DrugMatching Placebo

    Administered by SC injection

  • DrugICS/LABA

    Drug page: Fluticasone

    Administered at a blinded dose

    Also known as: fluticasone, propionate/salmeterol HFA, inhalation aerosol

06

What researchers measure

Primary outcomes

  1. Annualized severe asthma exacerbation rate

    Time frame: Baseline through Week 52

Secondary outcomes

  1. Change in pre-bronchodilator Forced expiratory volume in the first second (FEV1)

    Time frame: Baseline to week 12

  2. Annualized cumulative dose of systemic corticosteroid exposure to treat severe asthma exacerbations

    Time frame: Baseline to week 52

  3. Change in Asthma Control Questionnaire (ACQ-5)

    The ACQ-5 has 5 items that assess the most common asthma symptoms: 1. Frequency in past week awoken by asthma during the night, 2. Severity of asthma symptoms in the morning, 3. Limitation of daily activities due to asthma, 4. Shortness of breath due to asthma and 5. Wheeze. Participants are asked to recall how their asthma has been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The ACQ-5 global score is the mean of the 5 questions and, therefore, between 0 (totally controlled) and 6 (severely uncontrolled). Higher score indicates lower asthma control.

    Time frame: Baseline to week 12

  4. Proportion of participants achieving ACQ-5 <1.5

    Time frame: At week 12

  5. Change in pre-bronchodilator FEV1

    Time frame: Baseline up to week 52

  6. Change in percent predicted FEV1

    Time frame: Baseline up to week 52

  7. Change in peak expiratory flow (PEF)

    Time frame: Baseline up to week 52

  8. Change in forced vital capacity (FVC)

    Time frame: Baseline up to week 52

  9. Change in forced expiratory flow (FEF) 25-75%

    Time frame: Baseline up to week 52

  10. Change in FEV1: FVC ratio

    Time frame: Baseline up to week 52

  11. Change in post-bronchodilator FEV1

    Time frame: Baseline up to week 52

  12. Time to first severe exacerbation event

    Time frame: Up to week 52

  13. Proportion of participants achieving a 0.5-point improvement minimal clinically important difference (MCID) in ACQ-5

    Time frame: Up to week 52

  14. Incidence of Treatment-emergent adverse event (TEAEs)

    Time frame: Up to week 52

07

Study locations

77 sites
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has : received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.

Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 31 months is above that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2024
First posted
Aug 27, 2024
StartActual
Aug 26, 2024
Primary completionEst.
Apr 24, 2027
CompletionEst.
Apr 24, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06572228
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Aug 26, 2024
Primary completion
Apr 24, 2027 (estimated)
Completion
Apr 24, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion